Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice.

Autor: Li S; Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, PR China., Pan Y; Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, PR China., Ye R; Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, PR China., Wang Y; Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, PR China., Li L; Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, PR China. Electronic address: lilydlmu@hotmail.com.
Jazyk: angličtina
Zdroj: International immunopharmacology [Int Immunopharmacol] 2024 Dec 13; Vol. 146, pp. 113717. Date of Electronic Publication: 2024 Dec 13.
DOI: 10.1016/j.intimp.2024.113717
Abstrakt: In the last decade, advancements in immunotherapy knowledge have highlighted CTLA-4, PD-1, LAG-3, TIM-3, and TIGIT, decisive immune checkpoints exhibiting within the tumor microenvironment (TME), as fundamental objects for cancer immunotherapy. The widespread clinical use of immune checkpoint inhibitors (ICls), employing PD-1/PD-L1 or CTLA-4 antibodies to obstruct crucial checkpoint regulators, is noted in treating B-cell lymphoma patients. Nevertheless, the prolonged advantages of the currently employed treatments against CTLA-4, PD-1, and PD-L1 are uncommon among patients. Thus, recent focus has been progressively moved to additional immune checkpoints on T cells, like LAG-3, TIM-3, and TIGIT, which are now seen as reassuring targets for treatment and broadly acknowledged. There are several types of immunecheckpoint molecules expressed by T cells, and inhibitors targeting immune checkpoints can revive and amplify the immune response of T lymphocytes against tumors, a crucial aspect in lymphoma therapy. However, there is little knowledge about their regulation. Herein, we discuss the anti-tumor effects and functions of ICIs in controlling T-cell activity, as well as the progress in combined application with other immunotherapies.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: